Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Gastroesophageal Reflux 2Barrett Esophagus 2Zollinger-Ellison Syndrome 1Adenocarcinoma Of Esophagus 1

Interventions

Cisplatin 1514Carboplatin 1416Cyclophosphamide 1359Gemcitabine 1235Bevacizumab 1223Paclitaxel 1210Radiotherapy 1173Docetaxel 1079pembrolizumab 1026Oxaliplatin 934Capecitabine 898Fluorouracil 832Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 665Etoposide 660Irinotecan 622Leucovorin 574Pemetrexed 508Drug Therapy 491Cetuximab 481Trastuzumab 467Cytarabine 466Magnetic Resonance Spectroscopy 457Filgrastim 446Prednisone 432Lenalidomide 409Specimen Handling 407Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × YF 476 × Clear all
NCT01298999 2021-11-23

Trial of a Gastrin Receptor Antagonist in Barrett's Esophagus

Columbia University

Phase 2 Completed
27 enrolled 16 charts
Gastrointestinal

Adenocarcinoma Of Esophagus, Barrett Esophagus, Gastroesophageal Reflux

NCT02597712 2021-04-12

YF476 in Barrett's Esophagus

Trio Medicines Ltd.

Phase 2 Completed
27 enrolled 15 charts
Gastrointestinal

Barrett Esophagus, Gastroesophageal Reflux

NCT02454075 2021-01-29

YF476 and Type II Gastric Carcinoids

Trio Medicines Ltd.

Phase 2 Terminated
3 enrolled 11 charts

Zollinger-Ellison Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡